On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted in a series of narrow margins to recommend six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon—for the 503A Bulks List, directly overruling the agency's career scientists, who had advised against every one of them on grounds of insufficient human safety data. A seventh peptide, emideltide, failed by a 6-to-7 tally. The six compounds were narrowly recommended by the committee after two days of testimony.

The vote is advisory, and under Section 503A of the Federal Food, Drug, and Cosmetic Act, none of these peptides can be compounded by a licensed pharmacy until the FDA accepts the recommendation and completes notice-and-comment rulemaking—a proposed rule, a public comment period, and a final rule—a sequence that has not yet begun. The legal status of all six compounds on July 25 was identical to their status on July 22.

Scientists objected; the reconstituted panel overruled them

FDA scientific staff told the committee that none of the seven peptides under review had been proven safe or effective in humans, flagging unresolved synthesis impurities and potential immunogenicity risks. They recommended against inclusion for all seven. The panel voted past those objections on both days.

The committee's composition drew scrutiny before the first gavel. AJMC's follow-up reporting documented the reconstitution as adding clinicians and businesses involved in prescribing, producing, or promoting peptides—departing from the academic-researcher makeup typical of FDA advisory panels. The override lands while HHS Secretary Robert F. Kennedy Jr. moves to reclassify 14 of 19 restricted peptides back toward legal compounding status, a push he has sustained since February 2026.

For patients asking whether peptides are legal, the structural distinction matters: placement on the 503A Bulks List would let a compounding pharmacist prepare a patient-specific prescription from bulk ingredient. It carries none of the safety, efficacy, or manufacturing validation that accompanies full drug approval.

Rulemaking has not started; gray-market supply fills the gap

The FDA has not stated whether it will accept or reject the committee's recommendation. Until a final rule publishes in the Federal Register, providers cannot submit prescriptions expecting compliant 503A pharmacies to fill them, and pharmacies that compound these peptides now operate outside federal law regardless of the advisory vote. The gap between the vote and any legal compounding authority is measured in months of administrative procedure, not days.

In the interim, consumers have turned to alternative sources—including suppliers in China—purchasing peptides sold under "research use only" labels with no verified purity or standardized peptide testing. The panel's recommendation points toward a future in which a licensed pharmacist working from a prescription could prepare these compounds under professional oversight. That future remains separated from the present by a rulemaking process with no announced start date.

The next concrete step belongs to FDA leadership: a decision on whether to initiate proposed-rule publication for the six recommended peptides. No date for that decision has been announced.

Related Peptides Agora coverage examines fda approved peptides.